ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Inventory of New Drug Targets in 2023 roger
May 21, 2024In 2023, 49 new drugs received their first approval in the United States, the European Union, and Japan. -
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
August 08, 2019Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY? clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity. -
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
August 08, 2019Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY? clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.
Pharma Sources Insight January 2025
